MCID: ALL009
MIFTS: 50

Allergic Conjunctivitis

Categories: Eye diseases, Immune diseases

Aliases & Classifications for Allergic Conjunctivitis

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 15 17 72
Conjunctivitis, Allergic 44
Conjunctivitis Allergic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:11204
MeSH 44 D003233
NCIt 50 C34506
SNOMED-CT 68 20212001
UMLS 72 C0009766

Summaries for Allergic Conjunctivitis

Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to pollen allergy and giant papillary conjunctivitis. An important gene associated with Allergic Conjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Pheniramine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 75 Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the... more...

Related Diseases for Allergic Conjunctivitis

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 301)
# Related Disease Score Top Affiliating Genes
1 pollen allergy 32.5 RNASE3 IL5 IL13 ICAM1
2 giant papillary conjunctivitis 32.3 RNASE3 IL4 CXCL8 CCL11
3 atopic keratoconjunctivitis 31.4 RNASE3 IL5 IL4
4 papillary conjunctivitis 30.9 IL4 CXCL8 CCL11
5 cytokine deficiency 30.8 IL5 IL13
6 blepharoconjunctivitis 30.8 RNASE3 IL4 CCL11
7 dermatitis 30.6 IL5 IL4 IL13 CCL11
8 hypereosinophilic syndrome 30.4 RNASE3 IL5 IL4 IL13 CCL11
9 vernal keratoconjunctivitis 30.2 RNASE3 IL5 IL4 IL13 ICAM1 CCL11
10 latex allergy 30.0 RNASE3 IL5 IL4 IL13
11 scleritis 29.9 TNF IL5 IL4
12 autoimmune disease 29.9 TNF IL4 IL10
13 ige responsiveness, atopic 29.8 RNASE3 IL5 IL4 IL13 IL10
14 haemophilus influenzae 29.7 TNF CXCL8
15 allergic rhinitis 29.7 RNASE3 IL5 IL4 IL13 IL10 ICAM1
16 trachoma 29.7 TNF IL10
17 chronic conjunctivitis 29.6 RNASE3 IL5 IL4 IL13 ICAM1 CCL11
18 myasthenia gravis 29.5 TNF IL4 IL10
19 chlamydia 29.4 TNF IL4 IL10 CXCL8
20 allergic asthma 29.3 RNASE3 IL5 IL4 IL13 IL10 CCL11
21 uveitis 29.3 TNF IL4 IL10 ICAM1
22 allergic hypersensitivity disease 29.3 RNASE3 IL5 IL4 IL13 IL10 HRH1
23 food allergy 29.3 RNASE3 IL5 IL4 IL13 IL10
24 conjunctivitis 29.3 RNASE3 IL5 IL4 IL33 IL13 ICAM1
25 conjunctival disease 29.1 TNF RNASE3 IL5 IL4 IL13 CCL11
26 rhinitis 29.0 RNASE3 IL5 IL4 IL13 ICAM1 HRH1
27 bronchitis 28.7 TNF RNASE3 IL5 CXCL8 CCL11
28 keratoconjunctivitis 28.6 TNF RNASE3 IL5 IL4 IL13 ICAM1
29 contact dermatitis 28.1 TNF IL5 IL4 IL10 ICAM1 CXCL8
30 dermatitis, atopic 27.0 TNF RNASE3 IL5 IL4 IL13 IL10
31 proteasome-associated autoinflammatory syndrome 1 26.6 TNF RNASE3 IL5 IL4 IL13 IL10
32 asthma 26.1 TNF RNASE3 IL5 IL4 IL13 IL10
33 blepharitis 11.6
34 loeffler endocarditis 10.6 RNASE3 IL5
35 penicillin allergy 10.5 IL4 IL13
36 eye disease 10.5
37 pemphigoid gestationis 10.5 IL5 CCL11
38 respiratory syncytial virus infectious disease 10.5 IL5 IL13
39 egg allergy 10.5 IL5 IL4
40 sulfamethoxazole allergy 10.5 IL5 IL4
41 chronic meningitis 10.5 IL5 CCL11
42 trichinosis 10.5 IL5 IL4
43 non-suppurative otitis media 10.4 IL5 IL4
44 diversion colitis 10.4 IL4 ICAM1
45 ascaris lumbricoides infection 10.4 IL5 IL13
46 cough variant asthma 10.4 RNASE3 IL5 IL4
47 intrinsic asthma 10.4 RNASE3 IL5 IL4
48 paragonimiasis 10.4 RNASE3 IL5 IL13
49 hyperlucent lung 10.4 IL4 IL10
50 vernal conjunctivitis 10.4

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis

Symptoms & Phenotypes for Allergic Conjunctivitis

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCL11 HRH1 ICAM1 IL10 IL13 IL33
2 digestive/alimentary MP:0005381 9.98 ICAM1 IL10 IL13 IL33 IL4 IL5
3 homeostasis/metabolism MP:0005376 9.97 HRH1 ICAM1 IL10 IL13 IL33 IL4
4 immune system MP:0005387 9.96 CCL11 HRH1 ICAM1 IL10 IL13 IL33
5 endocrine/exocrine gland MP:0005379 9.95 ICAM1 IL10 IL13 IL33 IL4 TLR3
6 neoplasm MP:0002006 9.55 ICAM1 IL10 IL5 TLR3 TNF
7 reproductive system MP:0005389 9.5 IL10 IL13 IL33 IL4 IL5 TLR3
8 respiratory system MP:0005388 9.23 CCL11 IL10 IL13 IL33 IL4 IL5

Drugs & Therapeutics for Allergic Conjunctivitis

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Alcaftadine Approved Phase 4 147084-10-4 19371515
4
Bepotastine Approved Phase 4 125602-71-3, 190786-44-8 2350
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
6
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
11
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
16
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
17
Dipivefrin Approved Phase 4 52365-63-6 3105
18
Montelukast Approved Phase 4 158966-92-8 5281040
19
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
20
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
21
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
22
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
23
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
24
Tranilast Investigational Phase 4 53902-12-8 93543
25
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
26 Ketorolac Tromethamine Phase 4
27 Dermatologic Agents Phase 4
28 Antipruritics Phase 4
29 Pharmaceutical Solutions Phase 4
30 Lubricant Eye Drops Phase 4
31 Immunosuppressive Agents Phase 4
32 Calcineurin Inhibitors Phase 4
33 Hormone Antagonists Phase 4
34 Antiemetics Phase 4
35 Gastrointestinal Agents Phase 4
36 HIV Protease Inhibitors Phase 4
37 glucocorticoids Phase 4
38 Hormones Phase 4
39
protease inhibitors Phase 4
40 Antineoplastic Agents, Hormonal Phase 4
41 BB 1101 Phase 4
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
43 Platelet Aggregation Inhibitors Phase 4
44 calcium channel blockers Phase 4
45 Calcium, Dietary Phase 4
46 Dextrans Phase 4
47 Plasma Substitutes Phase 4
48 Anticoagulants Phase 4
49 Blood Substitutes Phase 4
50 Neuroprotective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
5 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
6 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
7 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
8 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
9 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
10 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
11 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
12 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
13 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
14 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
15 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
16 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
17 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
18 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
19 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
20 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
21 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
22 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
23 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
24 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
25 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
26 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
27 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
28 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
29 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
30 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
31 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
32 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis Completed NCT01918956 Phase 4
33 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
34 The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation Completed NCT02394600 Phase 4 Grastek®;Placebo
35 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
36 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
37 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
38 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
39 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
40 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
41 Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
42 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
43 The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
44 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
45 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
46 Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
47 A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy Not yet recruiting NCT03862053 Phase 4 Manuka honey
48 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study Terminated NCT00276445 Phase 4 beta-1,3-glucan
49 Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
50 A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis Unknown status NCT01012752 Phase 3

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alcaftadine
Antazoline
Antazoline Hydrochloride
Antazoline Phosphate
Astemizole
azelastine
Azelastine
Azelastine hydrochloride
bepotastine
bepotastine besilate
carbinoxamine
Carbinoxamine
Carbinoxamine maleate
Cortisone acetate
Cyproheptadine
Dexamethasone
Dexchlorpheniramine maleate
Diclofenac
Emedastine
Epinastine
Hydrocortisone
Ketorolac Tromethamine
Ketotifen
levocabastine
Levocabastine hydrochloride
Loteprednol
Loteprednol
loteprednol etabonate
medrysone
Methylprednisolone
Nedocromil
Nedocromil Sodium
olopatadine
Olopatadine
Olopatadine hydrochloride
pemirolast
Pemirolast potassium
Pheniramine
Prednisolone
Prednisone
Promethazine
Pyrilamine
Pyrilamine Maleate
PYRILAMINE TANNATE
Triprolidine
Triprolidine
Triprolidine Hydrochloride

Cochrane evidence based reviews: conjunctivitis, allergic

Genetic Tests for Allergic Conjunctivitis

Anatomical Context for Allergic Conjunctivitis

MalaCards organs/tissues related to Allergic Conjunctivitis:

41
Eye, Testes, Skin, T Cells, Bone, Lung, Thymus

Publications for Allergic Conjunctivitis

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 1678)
# Title Authors PMID Year
1
Clinical evaluation of total IgE in tears of patients with allergic conjunctivitis disease using a novel application of the immunochromatography method. 9 38
19779297 2009
2
Is serum total IgE levels a good predictor of allergies in children? 9 38
19813686 2009
3
Relationship between myopia and allergen-specific serum IgE levels in patients with allergic conjunctivitis. 9 38
19788663 2009
4
Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. 9 38
19558341 2009
5
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 9 38
20361659 2009
6
Serum allergen specific immunoglobulin E levels in patients with allergic conjunctivitis. 9 38
18850541 2008
7
The early efficacy of topical levocabastine in patients with allergic conjunctivitis. 9 38
17075271 2006
8
Allergens in Japanese patients with allergic conjunctivitis in autumn. 9 38
15389269 2005
9
Eotaxin-1 (CCL11) up-regulation in tears during seasonal allergic conjunctivitis. 9 38
15221302 2004
10
Correlations between allergen-specific IgE serum levels in patients with allergic conjunctivitis in spring. 9 38
15209463 2004
11
Tear and serum eosinophil cationic protein levels in seasonal allergic conjunctivitis. 9 38
14620169 2003
12
Human ocular mast cells. 9 38
12582326 2002
13
Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. 9 38
12431041 2002
14
Respiratory syncytial virus may be a pathogen in allergic conjunctivitis. 9 38
11995809 2002
15
The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. 9 38
11274077 2001
16
Genetics of allergic disease: evidence for organ-specific susceptibility genes. 9 38
11306967 2001
17
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 9 38
10756233 2000
18
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 9 38
10682966 2000
19
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 9 38
10606937 2000
20
[Measurement of total IgE in tears : the adaptation of an immunoenzyme technique and the value of investigating locally produced IgE in the diagnosis of chronic conjunctivitis]. 9 38
10432371 1999
21
Expression of ICAM-1 on conjunctival epithelium and ECP in tears and serum from children with allergic conjunctivitis. 9 38
10400487 1999
22
Tear IgE concentrations in allergic conjunctivitis. 9 38
9683958 1998
23
Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. 9 38
9420138 1997
24
Characterization of cytokine mRNA transcripts in conjunctival cells in patients with allergic conjunctivitis. 9 38
9191598 1997
25
Sustained eosinophil cationic protein release into tears after a single high-dose conjunctival allergen challenge. 9 38
8911697 1996
26
Eosinophil cationic protein in tears in allergic conjunctivitis. 9 38
8759270 1996
27
A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. 9 38
8626992 1996
28
Measurement of interleukin-4 and histamine in superficial cells of conjunctiva in patients with allergic conjunctivitis. 9 38
8670730 1996
29
Interleukin-4 and IgE in seasonal allergic conjunctivitis. 9 38
8887388 1996
30
Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. 9 38
8789546 1996
31
Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis. 9 38
7586697 1995
32
[Importance of the lacrymal levels (total IgE, specific IgE and albumin) for the study of allergic conjunctivitis]. 9 38
8185822 1994
33
The origin of keratopathy in chronic allergic eye disease: a histopathological study. 9 38
8253220 1993
34
One-year evaluation of clinical and immunological efficacy and safety of sublingual versus subcutaneous allergen immunotherapy in allergic conjunctivitis. 38
31209565 2019
35
Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. 38
31436181 2019
36
Mini-monoka stenting for patients with perennial allergic conjunctivitis. 38
30204032 2019
37
Increased Risk of Atopic Diseases in the Siblings of Patients with Autism Spectrum Disorder: A Nationwide Population-Based Cohort Study. 38
31435817 2019
38
Utility of the Pediatric Allergic Disease Quality of Life Questionnaire for childhood eczema. 38
30706447 2019
39
Comparative Effect of Feeding Human Milk as Opposed to Formula on Visual Function and Ocular Anatomy. 38
31368780 2019
40
The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. 38
31336653 2019
41
Glucocorticoid receptor modulators CpdX and CpdX-D3 exhibit the same in vivo antiinflammatory activities as synthetic glucocorticoids. 38
31227605 2019
42
Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. 38
31269237 2019
43
Relationship between tear eotaxin-2 and MMP-9 with ocular allergy and corneal topography in keratoconus patients. 38
31363950 2019
44
DNA-Based Hybrid Hydrogels Sustain Water-Insoluble Ophthalmic Therapeutic Delivery against Allergic Conjunctivitis. 38
31264833 2019
45
Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly. 38
31055787 2019
46
A Novel Approach of Drug Localization Through Development of Polymeric Micellar System Containing Azelastine HCl for Ocular Delivery. 38
31362666 2019
47
Short ragweed pollen promotes M2 macrophage polarization via TSLP/TSLPR/OX40L signaling in allergic inflammation. 38
31350466 2019
48
Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report. 38
31340775 2019
49
Diagnosing and managing allergic conjunctivitis in childhood: The allergist's perspective. 38
30742722 2019
50
Risk of Atopic Diseases among Siblings of Patients with Attention-Deficit Hyperactivity Disorder: A Nationwide Population-Based Cohort Study. 38
31207596 2019

Variations for Allergic Conjunctivitis

Expression for Allergic Conjunctivitis

Search GEO for disease gene expression data for Allergic Conjunctivitis.

Pathways for Allergic Conjunctivitis

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TNF TLR3 RNASE3 IL5 IL4 IL33
2
Show member pathways
13.59 TNF IL5 IL4 IL33 IL13 IL10
3
Show member pathways
13.45 TNF IL5 IL4 IL13 IL10 ICAM1
4
Show member pathways
13.35 TNF TLR3 IL5 IL4 IL13 IL10
5
Show member pathways
13.3 TNF IL5 IL4 IL33 IL13 IL10
6
Show member pathways
13.24 TNF IL5 IL4 IL13 IL10 CXCL8
7 12.74 IL5 IL4 IL13 CXCL8
8
Show member pathways
12.72 TNF RNASE3 IL5 IL4 IL13 IL10
9
Show member pathways
12.67 TNF TLR3 IL33 CXCL8
10
Show member pathways
12.57 TNF IL5 IL4 IL13 IL10
11
Show member pathways
12.52 TNF IL5 IL4 IL13
12 12.5 TNF TLR3 IL4 IL10
13
Show member pathways
12.5 TNF IL5 IL4 IL10
14
Show member pathways
12.33 IL5 IL4 IL13 IL10
15
Show member pathways
12.33 TNF IL5 IL4 IL13 CXCL8 CCL11
16
Show member pathways
12.25 TNF IL5 IL4 IL13 IL10 CXCL8
17
Show member pathways
12.17 TNF IL4 CXCL8 CCL11
18 12.15 TNF IL13 IL10 CXCL8
19
Show member pathways
12.13 TNF IL33 CXCL8
20
Show member pathways
12.12 TNF TLR3 IL33
21
Show member pathways
12.03 IL5 IL4 IL13 IL10 ICAM1 CXCL8
22 12 TNF IL4 ICAM1 CXCL8
23
Show member pathways
11.99 TNF TLR3 IL10
24 11.98 TNF IL5 IL4 IL10
25
Show member pathways
11.97 TNF IL4 IL13
26
Show member pathways
11.96 TLR3 IL5 IL13
27 11.86 TNF ICAM1 CXCL8
28 11.86 TNF IL10 CXCL8
29 11.86 TNF ICAM1 CXCL8
30 11.84 TNF IL5 IL4
31 11.82 IL5 IL4 IL13 ICAM1 CXCL8
32 11.81 TNF ICAM1 CXCL8
33
Show member pathways
11.79 TNF IL5 IL4 CXCL8
34 11.78 TNF IL5 IL4 IL33 IL13 IL10
35 11.74 TNF IL4 IL13 IL10 CCL11
36 11.72 TNF IL10 CXCL8
37 11.69 IL5 IL4 IL10 CCL11
38
Show member pathways
11.63 TNF ICAM1 CXCL8
39 11.57 TNF IL10 ICAM1 CXCL8
40 11.53 TNF IL5 IL4 IL13 CXCL8 CCL11
41 11.38 TNF IL10 ICAM1
42 11.36 TNF IL5 IL4 IL33 IL13
43 11.32 TNF IL4 IL13 IL10 ICAM1 CXCL8
44 11.29 TNF IL5 IL4 IL13 IL10
45 11.26 IL5 IL4 IL13 IL10
46 11.22 TNF IL4 IL13 IL10 ICAM1 CXCL8
47 11.14 TNF IL5 IL4 IL13 IL10 CXCL8
48 11.1 IL5 IL4 IL33 IL13 IL10 CCL11
49 11.09 TNF CXCL8
50 11 TNF IL5 IL4 IL13 IL10 CXCL8

GO Terms for Allergic Conjunctivitis

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF RNASE3 IL5 IL4 IL33 IL13
2 extracellular space GO:0005615 9.36 TNF TLR3 RNASE3 IL5 IL4 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.89 TNF TLR3 RNASE3 IL10
2 positive regulation of gene expression GO:0010628 9.89 TNF TLR3 IL4 IL33 IL13
3 response to lipopolysaccharide GO:0032496 9.87 IL13 IL10 ICAM1
4 positive regulation of angiogenesis GO:0045766 9.86 TLR3 CXCL8 CCL11
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 TNF TLR3 ICAM1
6 defense response GO:0006952 9.85 TNF TLR3 CXCL8
7 cellular response to tumor necrosis factor GO:0071356 9.85 ICAM1 CXCL8 CCL11
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 TNF IL5 IL10
9 response to virus GO:0009615 9.83 TNF TLR3 CCL11
10 cellular response to interferon-gamma GO:0071346 9.81 TLR3 ICAM1 CCL11
11 cellular response to interleukin-1 GO:0071347 9.8 ICAM1 CXCL8 CCL11
12 positive regulation of inflammatory response GO:0050729 9.79 TNF TLR3 IL33
13 cellular response to lipopolysaccharide GO:0071222 9.73 TNF IL10 ICAM1 CXCL8
14 positive regulation of interleukin-6 production GO:0032755 9.72 TNF TLR3 IL33
15 regulation of synapse organization GO:0050807 9.7 TNF IL10
16 positive regulation of interleukin-8 production GO:0032757 9.7 TNF TLR3
17 positive regulation of cytokine secretion GO:0050715 9.7 TNF IL10
18 immune response GO:0006955 9.7 TNF IL5 IL4 IL13 IL10 CXCL8
19 negative regulation of osteoclast differentiation GO:0045671 9.69 TLR3 IL4
20 leukocyte chemotaxis GO:0030595 9.69 IL10 CXCL8
21 eosinophil chemotaxis GO:0048245 9.69 HRH1 CCL11
22 extrinsic apoptotic signaling pathway GO:0097191 9.69 TNF TLR3 IL33
23 positive regulation of chemokine production GO:0032722 9.68 TNF TLR3
24 embryonic digestive tract development GO:0048566 9.67 TNF CXCL8
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 TNF IL10
26 negative regulation of growth of symbiont in host GO:0044130 9.66 TNF IL10
27 response to molecule of bacterial origin GO:0002237 9.65 IL10 CXCL8
28 positive regulation of podosome assembly GO:0071803 9.65 TNF IL5
29 positive regulation of immunoglobulin secretion GO:0051024 9.64 IL5 IL33
30 positive regulation of chemokine secretion GO:0090197 9.63 TNF IL33
31 positive regulation of interleukin-13 production GO:0032736 9.63 IL4 IL33
32 positive regulation of chemokine biosynthetic process GO:0045080 9.61 TNF TLR3
33 endothelial cell apoptotic process GO:0072577 9.61 TNF IL10
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.6 IL4 IL10
35 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL33
36 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.58 TNF ICAM1
37 positive regulation of B cell proliferation GO:0030890 9.58 IL5 IL4 IL13
38 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 TNF IL10
39 necroptotic signaling pathway GO:0097527 9.56 TNF TLR3
40 negative regulation of endothelial cell apoptotic process GO:2000352 9.56 IL4 IL13 IL10 ICAM1
41 inflammatory response GO:0006954 9.56 TNF TLR3 IL5 IL13 IL10 HRH1
42 type 2 immune response GO:0042092 9.54 IL4 IL10
43 microglial cell activation GO:0001774 9.54 TNF TLR3 IL13
44 regulation of isotype switching GO:0045191 9.52 IL4 IL10
45 positive regulation of macrophage activation GO:0043032 9.5 IL33 IL13 IL10
46 receptor biosynthetic process GO:0032800 9.48 TNF IL10
47 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
48 cytokine-mediated signaling pathway GO:0019221 9.23 TNF IL5 IL4 IL13 IL10 ICAM1

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF IL5 IL4 IL33 IL13 IL10
2 cytokine receptor binding GO:0005126 9.16 IL4 IL13
3 growth factor activity GO:0008083 9.13 IL5 IL4 IL10

Sources for Allergic Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....